Azarbarzin Kurt 4
4 · TELA Bio, Inc. · Filed Nov 13, 2019
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Azarbarzin Kurt
Director
Transactions
- Conversion
Common Stock
2019-11-13+19,982→ 280,790 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Series B Preferred Stock
2019-11-13−5,377,928→ 0 total(indirect: By HighCape Partners QP, L.P.)→ Common Stock (217,816 underlying) - Conversion
Warrant (right to buy)
2019-11-13+123,653→ 123,653 total(indirect: By HighCape Partners QP, L.P.)Exercise: $28.65From: 2017-11-13Exp: 2027-01-18→ Common Stock (5,008 underlying) - Conversion
Warrant (right to buy)
2019-11-13+1,665→ 1,665 total(indirect: By HighCape Partners, L.P.)Exercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (67 underlying) - Purchase
Common Stock
2019-11-08$13.00/sh+10,220$132,860→ 12,675 total(indirect: By HighCape Partners, L.P.) - Purchase
Common Stock
2019-11-08$13.00/sh+75,901$986,713→ 260,808 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Common Stock
2019-11-13+269→ 12,944 total(indirect: By HighCape Partners, L.P.) - Conversion
Common Stock
2019-11-13+2,931→ 15,875 total(indirect: By HighCape Partners, L.P.) - Conversion
Common Stock
2019-11-13+217,816→ 498,606 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Series A Preferred Stock
2019-11-13−493,357→ 0 total(indirect: By HighCape Partners QP, L.P.)→ Common Stock (19,982 underlying) - Conversion
Series A Preferred Stock
2019-11-13−6,643→ 0 total(indirect: By HighCape Partners, L.P.)→ Common Stock (269 underlying) - Conversion
Series B Preferred Stock
2019-11-13−72,417→ 0 total(indirect: By HighCape Partners, L.P.)→ Common Stock (2,931 underlying) - Conversion
Warrant (right to buy)
2019-11-13−123,653→ 0 total(indirect: By HighCape Partners QP, L.P.)Exercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (123,653 underlying) - Conversion
Warrant (right to buy)
2019-11-13−1,665→ 0 total(indirect: By HighCape Partners, L.P.)Exercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (1,665 underlying)
Footnotes (6)
- [F1]Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F2]Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F3]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F5]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F6]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.